Sandoz Accuses United Therapeutics Of Blocking Generic Remodulin
A Sandoz lawsuit has accused United Therapeutics of trying to illegally block sales of the first US generic version of Remodulin.
You may also be interested in...
Sandoz has claimed the first US launch of a generic rival to Remodulin with 180-day exclusivity, following a settlement deal struck with United Therapeutics four years ago.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.